369652-04-0

Basic information

• Product Name: 2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl)
• Synonyms: 2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl)
• CAS NO: 369652-04-0
• Molecular Formula: C₁₁H₁₃N₃
• Molecular Weight: 187.24102
• Mol File: 369652-04-0.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl)(369652-04-0)
• EPA Substance Registry System: 2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl)(369652-04-0)

Safety Data

• Hazardous Substances Data: 369652-04-0(Hazardous Substances Data)

Usage

General Description

2-(1-phenyl-1H-pyrazol-4-yl)ethanamine, also known as SALTDATA: HCl, is a chemical compound with the molecular formula C11H14N2. It is a type of amine, containing a pyrazole ring and a phenyl group. The compound is typically found in the form of its hydrochloride salt. It is often used in pharmaceutical research and drug development due to its potential biological activities, such as its role as a selective serotonin reuptake inhibitor (SSRI). The compound's structure and properties make it a valuable tool for studying neurotransmitter systems and developing new medications for various psychiatric and neurological disorders. Additionally, 2-(1-phenyl-1H-pyrazol-4-yl)ethanamine has also been explored for its potential as a psychoactive substance.

Upstream product

• 54605-72-0 1-phenyl-1H-pyrazole-4-carbaldehyde 

Relevant articles and documents

Synthesis and 5-HT2A antagonist activity of derivatives of the novel heterocycles indolo[3,2-d]pyrrolo[3,2-g]azecine and benzo[d]pyrrolo[3,2-g]azecine compared to the benz[d]indolo[2,3-g]azecine derivative LE 300

An indolo[3,2-d]pyrrolo[3,2-g]azecine and a benzo[d]pyrrolo[3,2-g]azecine analogue of the potent dopamine receptor antagonist LE 300 (7-methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine) have been prepared in multi-step reactions via C-N bond cleavage of corresponding quaternary N-methylquinolizinium iodides. LE 300, the target compounds and two precursor quinolizines have been tested in vitro for antagonist activity at 5-HT2A receptors (rat tail artery) and H1 receptors (guinea-pig ileum), respectively. LE 300 and compound 19 (3,6-dimethyl-4, 5,6,7,8,13-hexahydro-3H-benzo[d]pyrrolo[3,2-g]azecine) competitively inhibited 5-HT-induced contractions with similar nanomolar potency (pA2 = 8.32 and 8.01, respectively) but were less active than the reference antagonist ketanserin (pA2 = 9.55). Compound 19 displayed moderate H1-antihistaminic activity in the guinea-pig ileum assay (pA2 = 7.37).